Is Omega-3 Triglyceride Randomized Trial safe?

The current Migaku evidence database contains 2 reusable source documents for Omega-3 Triglyceride Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts. - The results showed that CRP levels increased from 9.86 ± 12.64 to 11.46 ± 22.23 mg/L in the intervention group and from 5.24 ± 9.01 to 5.61 ± 7.93 mg/L in the control group (p = 0.11). [Shafaei Kachaei H (2026); evidence level 2] - Similarly, IL-6 levels increased from 17.84 ± 14.08 to 81.82 ± 66.22 pg/mL in the intervention group and from 14.96 ± 18.41 to 56.73 ± 115.45 pg/mL in the control group (p = 0.53). [Shafaei Kachaei H (2026); evidence level 2] - ○ Omega-3 fatty acids have anti-inflammatory properties and are reported to be potentially beneficial in reducing inflammation associated with CKD, but the evidence regarding the effectiveness of omega-3 supplements in reducing inflammatory markers in this population remains inconsistent. [Shafaei Kachaei H (2026); evidence level 2] - This randomized controlled trial aimed to evaluate the effects of omega-3 fatty acids supplementation on inflammatory markers in patients with CKD undergoing hemodialysis. [Shafaei Kachaei H (2026); evidence level 2] - The updated terminology introduces “metabolic dysfunction-associated steatotic liver disease” (MASLD) to replace NAFLD and “metabolic dysfunction-associated steatohepatitis” (MASH) to replace nonalcoholic steatohepatitis. [Tamehri Zadeh Seyed Saeed (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.